Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

Abstract

Background The TRUSTY study evaluated the efficacy of second-line trifluridine/tipiracil (FTD/TPI) plus bevacizumab in metastatic colorectal cancer (mCRC). Objective This exploratory biomarker analysis of TRUSTY investigated the relationship between baseline plasma concentrations of angiogenesis-related factors and cell-free DNA (cfDNA), and the efficacy of FTD/TPI plus bevacizumab in patients with mCRC. Patients and Methods The disease control rate (DCR) and progression-free survival (PFS) were compared between baseline plasma samples of patients with high and low plasma concentrations (based on the median value) of angiogenesis-related factors. Correlations between cfDNA concentrations and PFS were assessed. Results Baseline characteristics ( n = 65) were as follows: male/female, 35/30; median age, 64 (range 25–84) years; and RAS status wild-type/mutant, 29/36. Patients in the hepatocyte growth factor (HGF)-low and interleukin (IL)-8-low groups had a significantly higher DCR (risk ratio [95% confidence intervals {CIs}]) than patients in the HGF-high (1.83 [1.12–2.98]) and IL-8-high (1.70 [1.02–2.82]) groups. PFS (hazard ratio {HR} [95% CI]) was significantly longer in patients in the HGF-low (0.33 [0.14–0.79]), IL-8-low (0.31 [0.14–0.70]), IL-6-low (0.19 [0.07–0.50]), osteopontin-low (0.39 [0.17–0.88]), thrombospondin-2-low (0.42 [0.18–0.98]), and tissue inhibitor of metalloproteinase-1-low (0.26 [0.10–0.67]) groups versus those having corresponding high plasma concentrations of these angiogenesis-related factors. No correlation was observed between cfDNA concentration and PFS. Conclusion Low baseline plasma concentrations of HGF and IL-8 may predict better DCR and PFS in patients with mCRC receiving FTD/TPI plus bevacizumab, however further studies are warranted. Clinical Trial Registration Number jRCTs031180122. Supplementary Information The online version contains supplementary material available at 10.1007/s11523-023-01027-8.

A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G

“…Second, a U-kit was used for the biomarker analyses, which might have produced inconsistent findings. However, feasible results using this kit have been already reported in a few papers [ 16 ] [ 19 ] [ 29 ]. Third, while the median value was used as the cut-off for each angiogenesis factor, it may not be easy to establish the appropriate cut-off values in different treatments.…”

Elucidating the role of angiogenesis-related genes in colorectal cancer: a multi-omics analysis

“…As a result, targeting angiogenesis has emerged as a promising therapeutic strategy in CRC treatment. For instance, anti-angiogenic drugs like bevacizumab, a monoclonal antibody against VEGF, have demonstrated enhanced patient outcomes when used in conjunction with traditional chemotherapy regimens ( 10 , 11 ).…”

Table_1.docx

“…As a result, targeting angiogenesis has emerged as a promising therapeutic strategy in CRC treatment. For instance, antiangiogenic drugs like bevacizumab, a monoclonal antibody against VEGF, have demonstrated enhanced patient outcomes when used in conjunction with traditional chemotherapy regimens (10,11).…”